- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 92,170 | 09.07.24 11:46:20 | -0,340 | -0,37% | 92,080 | 92,250 | 92,710 | 92,510 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 981,600 | 09.07.24 12:01:25 | +21,400 | +2,23% | 971,800 | 977,000 | 970,200 | 960,200 |
